Defining the impact of chronic lung disease on COVID-19 and developing effective therapies
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA204228
Grant search
Key facts
Disease
COVID-19Start & end year
20222025Known Financial Commitments (USD)
$646,759.51Funder
National Health and Medical Research Council (NHMRC)Research Location
AustraliaLead Research Institution
University of SydneyResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Supportive care, processes of care and managementSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
COVID-19 disease is driven by virus-induced, hyper-inflammation that damages the lungs. Patients with chronic lung disease, such as chronic obstructive pulmonary disease (COPD) and tuberculosis (TB), have increased severity of COVID-19 disease. Using our models of TB and smoking-induced COPD, we will define how chronic lung disease increases the severity of COVID-19, how CoV2 infection exacerbates TB and COPD, and identify effective drugs that suppress this inflammatory damage to the lung.